
Artivion (AORT) Stock Forecast & Price Target
Artivion (AORT) Analyst Ratings
Bulls say
Artivion Inc. has demonstrated a significant operating margin improvement, reporting 17.8%, an increase of 770 basis points year over year, and exceeding prior estimates, indicating operational efficiency. The company anticipates further enhancement in gross margins, with projections for a 100 basis point increase in 2025 and an anticipated rise in adjusted EBITDA margin to 18.1%, reflecting ongoing strength in revenue generation. Additionally, the successful launch of AMDS is expected to contribute modestly to revenue growth, supported by robust gains in sales across key product lines such as On-X, aortic stent grafts, and BioGlue, bolstering a positive outlook for Artivion's financial performance.
Bears say
Artivion Inc. faces significant risks impacting its financial performance, including potential delays in clinical trials and new product approvals, which could lead to disappointing sales from new offerings and a weaker operating margin due to increased reinvestment. The company's recent quarterly results showed a decline in top-line revenue growth, dropping to 3.5% in Q4 2024 from 9.5% in Q3 2024, largely attributed to a cybersecurity incident that negatively affected sales by approximately $4.5 million. Furthermore, the bear case scenario indicates a concerning trend of revenue growth potentially slowing to the low- to mid-single digits, driven by underwhelming international expansion and new product launches.
This aggregate rating is based on analysts' research of Artivion and is not a guaranteed prediction by Public.com or investment advice.
Artivion (AORT) Analyst Forecast & Price Prediction
Start investing in Artivion (AORT)
Order type
Buy in
Order amount
Est. shares
0 shares